Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02522715 · ClinicalTrials.gov registry record · Phase 1

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

A Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute.

Active
Registry status
Phase 1
Development phase
37
Enrollment target
3
Study locations

NCT02522715: Active Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute.

NCT02522715 is a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 37 participants, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (52% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02522715, a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
37 participants
Enrollment target
3
Study locations

Study Summary

This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer responds to treatment with hormones (hormone-resistant). Drugs used in chemotherapy, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Androgen can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of androgen by the tumor cells. Giving cabazitaxel together with enzalutamide may work better in treating metastatic, hormone-resistant prostate cancer.

Primary Outcome

The percentage of participants will be reported with 95% confidence interval using exact method.

Conditions Studied

Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer AJCC v7

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Prednisone
  • DRUG Enzalutamide
  • DRUG Cabazitaxel
  • OTHER Pharmacological Study

Study Locations (3)

Oregon

  • OHSU Knight Cancer Institute - Portland
  • Portland VA Medical Center - Portland

Washington

  • Seattle Cancer Care Alliance - Seattle

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2015-08-13
Est. Completion 2027-01-01
Phase Phase 1
OHSU Knight Cancer Institute

211 total trials

What the registry record for NCT02522715 still lists

NCT02522715 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (52% lower).

The record links to 4 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02522715 reports a single indexed study location in Oregon, Washington.

Frequently Asked Questions

What is clinical trial NCT02522715 about?

NCT02522715 is a clinical study titled "Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer". This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer responds to treatment wit...

What is the current status of trial NCT02522715?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2015-08-13. Estimated completion is 2027-01-01.

What conditions does trial NCT02522715 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7.

What interventions are being tested in trial NCT02522715?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Prednisone (DRUG), Enzalutamide (DRUG), Cabazitaxel (DRUG), Pharmacological Study (OTHER).

Who is sponsoring clinical trial NCT02522715?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02522715 being conducted?

This trial has 3 study locations across Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02522715's enrollment target sits among peer trials

37 23rd of 43 higher than 21 of 43 other Castration-Resistant Prostate Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Castration-Resistant Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02522715, the US trial registry maintained by the National Library of Medicine. NCT02522715 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.